CL2022000194A1 - Uso para tratar la enfermedad de hemorragia alveolar difusa asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384) - Google Patents

Uso para tratar la enfermedad de hemorragia alveolar difusa asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384)

Info

Publication number
CL2022000194A1
CL2022000194A1 CL2022000194A CL2022000194A CL2022000194A1 CL 2022000194 A1 CL2022000194 A1 CL 2022000194A1 CL 2022000194 A CL2022000194 A CL 2022000194A CL 2022000194 A CL2022000194 A CL 2022000194A CL 2022000194 A1 CL2022000194 A1 CL 2022000194A1
Authority
CL
Chile
Prior art keywords
stem cell
hematopoietic stem
disease associated
cell transplantation
divisional application
Prior art date
Application number
CL2022000194A
Other languages
English (en)
Inventor
Gregory A Demopulos
Thomas Dudler
Hans-Wilhelm Schwaeble
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Publication of CL2022000194A1 publication Critical patent/CL2022000194A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En un aspecto, la invención proporciona usos para tratar la inhibición de los efectos de la activación del complemento dependiente de MASP-2 en un sujeto humano que padece la enfermedad de hemorragia alveolar difusa asociada con un trasplante de células madre hematopoyéticas Los usos comprenden la etapa de administrar a un sujeto que lo necesita una cantidad de un agente inhibidor de MASP-2 efectiva para inhibir la activación del complemento dependiente de MASP-2.
CL2022000194A 2017-08-15 2022-01-25 Uso para tratar la enfermedad de hemorragia alveolar difusa asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384) CL2022000194A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762545864P 2017-08-15 2017-08-15
US201762574690P 2017-10-19 2017-10-19
US201862630756P 2018-02-14 2018-02-14
US201862637281P 2018-03-01 2018-03-01

Publications (1)

Publication Number Publication Date
CL2022000194A1 true CL2022000194A1 (es) 2023-01-27

Family

ID=65362042

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2020000384A CL2020000384A1 (es) 2017-08-15 2020-02-14 Métodos para tratar y/o prevenir la enfermedad de injerto contra huésped y/o hemorragia alveolar difusa y/o enfermedad veno-oclusiva asociada con trasplante de células madre hematopoyéticas.
CL2022000194A CL2022000194A1 (es) 2017-08-15 2022-01-25 Uso para tratar la enfermedad de hemorragia alveolar difusa asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384)
CL2022000195A CL2022000195A1 (es) 2017-08-15 2022-01-25 Usos para tratar la enfermedad veno-oclusiva asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2020000384A CL2020000384A1 (es) 2017-08-15 2020-02-14 Métodos para tratar y/o prevenir la enfermedad de injerto contra huésped y/o hemorragia alveolar difusa y/o enfermedad veno-oclusiva asociada con trasplante de células madre hematopoyéticas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2022000195A CL2022000195A1 (es) 2017-08-15 2022-01-25 Usos para tratar la enfermedad veno-oclusiva asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384)

Country Status (18)

Country Link
US (2) US11013772B2 (es)
EP (1) EP3668531A4 (es)
JP (2) JP2020531452A (es)
KR (1) KR20200040805A (es)
CN (1) CN111278449A (es)
AU (1) AU2018318982A1 (es)
BR (1) BR112020003207A2 (es)
CA (1) CA3072940A1 (es)
CL (3) CL2020000384A1 (es)
GE (1) GEP20237541B (es)
IL (1) IL272674A (es)
JO (1) JOP20200021A1 (es)
MA (1) MA49915A (es)
MX (1) MX2020001728A (es)
PH (1) PH12020500276A1 (es)
SG (1) SG11202001014WA (es)
TW (2) TWI818919B (es)
WO (1) WO2019036460A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
US20220064330A1 (en) * 2019-11-26 2022-03-03 Omeros Corporation Methods for treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplant
CA3159159A1 (en) 2019-12-04 2021-06-10 Neil S. Cutshall Masp-2 inhibitors and methods of use
IL293551A (en) 2019-12-04 2022-08-01 Omeros Corp 2-masp inhibitor compounds, preparations containing them and their uses
AU2020398241A1 (en) 2019-12-04 2022-06-30 Omeros Corporation MASP-2 inhibitors and methods of use
EP4069238A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
CN113057142B (zh) * 2021-03-30 2022-12-09 四川大学华西医院 一种视网膜内和/或视网膜下纤维化动物模型的构建方法
CN114532982A (zh) * 2022-01-12 2022-05-27 高谋 评价干细胞系统移植调控补体活化作用的体系
CN114686585B (zh) * 2022-04-01 2023-06-30 中国人民解放军总医院 Tmem65在预警和/或治疗高原病中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526909A (en) 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
ATE115999T1 (de) 1987-12-15 1995-01-15 Gene Shears Pty Ltd Ribozyme.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
BR9509985A (pt) 1995-12-12 1998-11-03 Omeros Med Sys Inc Solução para irrigação e método para inibição de dor inflamação e esparmo
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
ATE399025T1 (de) 1999-07-21 2008-07-15 Omeros Corp Spüllösungen und verfahren zur schmerzhemmung, entzündungshemmung und hemmung des knorpelabbaus
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
MXPA04007124A (es) 2002-02-01 2004-10-29 Omeros Corp Composiciones y metodos para la inhibicion sistemica de la degradacion del cartilago.
JP4723244B2 (ja) 2002-07-19 2011-07-13 オメロス コーポレイション 生分解性トリブロックコポリマー、その合成方法、ならびにそれから作製されるヒドロゲルおよび生体材料
HUE024996T2 (en) 2003-05-12 2016-01-28 Helion Biotech Aps Anti-MASP-2 antibodies
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20080193414A1 (en) * 2005-05-06 2008-08-14 Amanda Proudfoot Use of an Immunoglobulin Domain-Containing Cell Surface Recognition Molecule For Treating Diseases
JP6033774B2 (ja) 2010-07-21 2016-11-30 イースタン ヴァージニア メディカル スクールＥａｓｔｅｒｎ Ｖｉｒｇｉｎｉａ Ｍｅｄｉｃａｌ Ｓｃｈｏｏｌ 補体系を調節するためのペプチド化合物
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20150166676A1 (en) * 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
ME03755B (me) * 2011-05-04 2021-04-20 Omeros Corp Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa
CN108350086A (zh) 2013-01-23 2018-07-31 南卡罗来纳医科大学研究发展基金会 基于天然抗体的靶向构建体及其用途
ES2829913T3 (es) * 2013-10-17 2021-06-02 Omeros Corp Procedimientos de tratamiento de afecciones asociadas con la activación del complemento dependiente de MASP-2
EP3151845A4 (en) * 2014-06-05 2018-01-17 The Regents of the University of Colorado, a body corporate Map44 polypeptides and constructs based on natural antibodies and uses thereof
WO2016198133A1 (en) 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
GEP20247583B (en) * 2015-11-09 2024-01-10 Univ Leicester Methods for treating condi tions associated with masp-2 dependent complement activation

Also Published As

Publication number Publication date
AU2018318982A2 (en) 2020-03-26
KR20200040805A (ko) 2020-04-20
CL2022000195A1 (es) 2023-01-27
CN111278449A (zh) 2020-06-12
WO2019036460A1 (en) 2019-02-21
IL272674A (en) 2020-03-31
PH12020500276A1 (en) 2020-09-21
TW202402809A (zh) 2024-01-16
US20190125802A1 (en) 2019-05-02
US20210290684A1 (en) 2021-09-23
JOP20200021A1 (ar) 2020-02-02
CA3072940A1 (en) 2019-02-21
AU2018318982A1 (en) 2020-03-19
TWI818919B (zh) 2023-10-21
BR112020003207A2 (pt) 2020-10-06
SG11202001014WA (en) 2020-03-30
US11896621B2 (en) 2024-02-13
JP2020531452A (ja) 2020-11-05
MX2020001728A (es) 2020-09-25
CL2020000384A1 (es) 2020-08-14
TW201920288A (zh) 2019-06-01
US11013772B2 (en) 2021-05-25
GEP20237541B (en) 2023-09-25
MA49915A (fr) 2021-03-24
JP2023123627A (ja) 2023-09-05
EP3668531A4 (en) 2021-03-24
EP3668531A1 (en) 2020-06-24

Similar Documents

Publication Publication Date Title
CL2022000194A1 (es) Uso para tratar la enfermedad de hemorragia alveolar difusa asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384)
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
CL2018001557A1 (es) Uso de un agente inhibidor de masp-2 que inhibe la activación del complemento dependiente de masp-2, para tratar un sujeto que padece de síndrome antifosfolipido catastrófico (safc). (solicitud divisional 201600908)
CO2019008487A2 (es) Compuesto de quinazolina
CO2018012894A2 (es) Derivados de pirazol como inhibidores de calicreína plasmática
DOP2017000271A (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
CL2018001258A1 (es) Métodos para tratar las condiciones asociadas con la activación del complemento dependiente de masp-2
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
ECSP20082339A (es) Moduladores de la expresión de apol1
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
ECSP23076906A (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
CL2021000107A1 (es) Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
ECSP20016283A (es) Métodos para tratar y/o prevenir la enfermedad del injerto frente a hospedador y/o hemorragia alveolar y/o enfermedad veno-oclusiva asociada a trasplante de células madre hematopoyéticas
CL2023000702A1 (es) Usos de inhibidores de masp-2 para tratar la enfermedad de células falciformes